Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

This study evaluates a sensor-controlled digital game (SCDG) to motivate self-management behaviors of weight monitoring and physical activity in adults with heart failure (HF). Half of the participants will receive the SCDG app and weight monitoring and physical activity sensors and the other half will receive only the weight monitoring and physical activity sensors.

The overall objective of research is to test, adapt, refine and validate the HEMOTAG® system to be used outside the usual medical care environments to reduce hospital readmissions.

Are you an adult who has had Fontan palliation operation? If so, you may be able to join a clinical trial where researchers learn more about how the heart and lungs work after a Fontan palliation. Researchers will perform a procedure called a cardiac catheterization while participants exercise to see how well the heart is working. Participants must be at least 18 years old. The study is taking place in Rochester, Minnesota.

Are you an adult with mild heart failure and a left bundle branch block? This study will test whether a type of pacemaker called a cardiac resynchronization device can help the heart pump more blood in people who have mild heart failure (HF) and left bundle branch block. In the study, participants will have a cardiac resynchronization device implanted. This study is located in Bethesda, Maryland.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Are you an adult with mild heart failure (HF) and left bundle branch block (LBBB)? LBBB is a heart condition in which there is a delay or blockage of electrical signals to the left side of the heart. This study is exploring the use of a treatment called cardiac resynchronization therapy (CRT) in people with HF and LBBB. To have CRT, participants must be willing to have an implanted device, called a biventricular pacemaker, that helps the chambers of the heart work together to pump blood more efficiently. To participate in this study, you must be at least 18 years old. This study takes place in Rochester, Minnesota.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.

Are you an adult who is healthy or has problems with the level of cholesterol or other lipids in the blood? This study is gathering information on the risk factors for very high or very low levels of lipids, or fats, in the blood. Researchers will collect participants’ demographic information, medical history, and blood samples. To participate in this study, you must be at least 18 years old. This study takes place in Dallas, Texas.

Are you between 40 and 85 with worsening idiopathic pulmonary fibrosis? This study aims to test a new combination treatment for acute exacerbations, a life-threatening complication of idiopathic pulmonary fibrosis (IPF) that has no approved treatment. The treatment is meant to help stop part of the immune system from further injuring the lung tissue. To participate in this study, you must be between 40 and 85 years old and have worsening IPF. This study is located in Birmingham, Alabama; Boston, Massachusetts; Philadelphia, Pennsylvania; and Pittsburgh, Pennsylvania.